Publication Name	World Journal of Hepatology
Manuscript ID	105797
Country	China

Received	2025-02-08 06:41
Peer-Review Started	2025-02-08 06:41
To Make the First Decision
Return for Revision	2025-03-10 02:44
Revised	2025-03-21 09:05
Second Decision	2025-04-09 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-04-09 08:50
Articles in Press	2025-04-09 08:50
Publication Fee Transferred	2025-03-24 07:05
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-04-18 01:05
Publish the Manuscript Online	2025-04-25 08:23

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Minireviews
Article Title	Drug development for chronic hepatitis B functional cure: Recent progress
Manuscript Source	Unsolicited Manuscript
All Author List	Ting Liu, He Wang, Yue Zhao, Ying-Xin Wang, Xue Xing and Peng Gao
ORCID	Author(s) ORCID Number Ting Liu http://orcid.org/0009-0005-3449-5210 Xue Xing http://orcid.org/0009-0003-4650-0684 Peng Gao http://orcid.org/0000-0001-6932-5370
Funding Agency and Grant Number
Corresponding Author	Peng Gao, PhD, Professor, Department of Clinical Laboratory, The Second Affiliated Hospital of Dalian Medical University, No. 467 Zhongshan Road, Dalian 116021, Liaoning Province, China. gaop@dmu.edu.cn
Key Words	Chronic hepatitis B infection; Therapeutic targets; Monoclonal antibody; RNA interference; Immunomodulators
Core Tip	As we know, chronic hepatitis B virus (HBV) infection can lead to liver failure and cirrhosis, resulting in significantly increased morbidity and mortality rates. Current antiviral nucleos(t)ide analogues suppress HBV replication but are limited in reducing hepatitis B surface antigen (HBsAg) levels. Interferon alpha, an immunomodulator, is restricted by safety concerns and adverse reactions. New drug development aims for a functional cure, defined as HBsAg clearance and sustained HBV DNA suppression. This review highlights recent advancements in novel therapies targeting HBV, including HBsAg entry inhibitors, monoclonal antibodies, transcription inhibitors, and immunomodulatory agents like TLR-7/8 agonists, immune checkpoint inhibitors, and therapeutic vaccines.
Publish Date	2025-04-25 08:23
Citation	<p>Liu T, Wang H, Zhao Y, Wang YX, Xing X, Gao P. Drug development for chronic hepatitis B functional cure: Recent progress. <i>World J Hepatol</i> 2025; 17(4): 105797</p>
URL	https://www.wjgnet.com/1948-5182/full/v17/i4/105797.htm
DOI	https://dx.doi.org/10.4254/wjh.v17.i4.105797

Full Article (PDF)	WJH-17-105797-with-cover.pdf
Manuscript File	105797_Auto_Edited_012717.docx
Answering Reviewers	105797-answering-reviewers.pdf
Audio Core Tip	105797-audio.m4a
Conflict-of-Interest Disclosure Form	105797-conflict-of-interest-statement.pdf
Copyright License Agreement	105797-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	105797-non-native-speakers.pdf
Supplementary Material	105797-supplementary-material.pdf
Peer-review Report	105797-peer-reviews.pdf
Scientific Editor Work List	105797-scientific-editor-work-list.pdf
CrossCheck Report	105797-crosscheck-report.pdf